Highlights Notable Labs, Ltd.

Equities

NTBL

IL0012002452

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.914 ^USD	-0.65%		-6.82%	-51.64%

Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9, Keeps Buy Rating	MT
Apr. 15	Chardan Cuts Price Target on Notable Labs to $7 From $9 on Higher Projected Future Share Count, Keeps Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Notable Labs, Ltd. Presents the Design Plan for the Ppmp-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024	Apr. 09	CI
Notable Labs Presentation of Data Related to Innovations in the Use of Cryopreserved Samples in the PPMP Assay At AACR 2024 Expands the Potential of the Platform	Apr. 08	CI
Notable Labs, Ltd. Advances Volasertib Phase 2 Program Utilizing Proprietary Predictive Precision Medicine Platform-Guided Enrollment	Feb. 22	CI
Notable Labs, Ltd. and CicloMed LLC Announces Initial Safety and Efficacy Data of Fosciclopirox and the Performance of PPMP	Dec. 18	CI
Vascular Biogenics, Notable Labs Complete Merger	23-10-16	MT
Notable Labs, Inc. completed the acquisition of Vascular Biogenics Ltd. from Aurum Ventures MKI Ltd. and others in reverse merger transaction.	23-10-15	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Vascular Biogenics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
An unknown buyer completed the acquisition of Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd..	23-03-08	CI
Aleph Farms Limited completed the acquisition of manufacturing facility in Israel from Vascular Biogenics Ltd..	23-03-08	CI
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT	23-02-27	BU
Vascular Biogenics Ltd. and Notable Labs Merger Call	23-02-23	FA
Vascular Biogenics, Notable Labs Sign Merger to Form Nasdaq-Listed Therapeutic Platform Company	23-02-23	MT
VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement	23-02-23	AQ
Notable Labs, Inc. agreed to acquire Vascular Biogenics Ltd. in reverse merger transaction for $42 million.	23-02-22	CI
Aleph Farms Limited entered into an Asset Purchase Agreement to acquire manufacturing facility in Israel from Vascular Biogenics Ltd. for $7.1 million.	23-02-15	CI
An unknown buyer entered into an agreement to acquire Manufacturing facility in Modiin, Israel and certain related assets from Vascular Biogenics Ltd. for $7.1 million.	23-02-15	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Vascular Biogenics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Notable Labs, Ltd.

Equities

NTBL

IL0012002452

Highlights

Filters